食管鳞状细胞癌术后放化疗中扩大临床靶区照射:一项II期临床试验(ESO-Shanghai 9)
本研究为单臂II期试验,纳入70例食管鳞状细胞癌根治性经胸切除术后3个月内、切缘阴性的患者,术后给予扩大临床靶区照射45 Gy/25次并同步每周TC方案化疗5周期。2年局部控制率为87.9%(95%CI:83.3-92.3),达到预设至少83%的假设值,总生存、无病生存、局部区域无复发生存和无远处转移生存均较ESO-Shanghai 8研究延长,但多数毒性增加,2例死于放射性肺炎。
要点
- 术后扩大靶区45 Gy/25次同步TC方案化疗的2年局部控制率为87.9%(95%CI:83.3-92.3),达到预设至少83%的假设值。
- 总生存、无病生存、局部区域无复发生存和无远处转移生存均较ESO-Shanghai 8研究延长。
- 多数毒性较ESO-Shanghai 8研究增加,本研究中2例患者死于放射性肺炎。
核心结论
- 术后扩大靶区照射并提高放疗剂量联合同步化疗是有效的。
- 由于治疗强度提高,治疗相关毒性增加。
研究设计与样本
- 本研究为单臂II期临床试验(ESO-Shanghai 9,ClinicalTrials.gov注册号NCT02916511)。
- 纳入2016年至2018年共70例患者,均为接受根治性经胸切除、切缘阴性且在术后3个月内、组织学确诊的食管鳞状细胞癌(pT3-4N0M0或pTxN+M0,AJCC第7版)。
- 术后放疗总剂量45 Gy,分25次,临床靶区包括瘤床、吻合口、双侧锁骨上、纵隔、胃左及腹腔干淋巴结区。
- 同步化疗为每周TC方案5周期(紫杉醇50 mg/m2,第1天;卡铂AUC=2,第1天)。
- 主要终点为2年局部控制率,次要终点为总生存、无病生存、局部区域无复发生存、无远处转移生存和不良事件,所有终点均与ESO-Shanghai 8研究(术后单纯放疗40 Gy/20次)进行比较。
主要发现
- 本研究的2年局部控制率为87.9%(95%CI:83.3-92.3),达到预设至少83%的假设值。
- 本研究的总体生存、无病生存、局部区域无复发生存和无远处转移生存均较既往ESO-Shanghai 8研究延长。
- 多数毒性增加,本研究中2例患者死于放射性肺炎。
关键数值与推荐
- 术后放疗总剂量45 Gy,分25次。
- 同步化疗为每周TC方案5周期:紫杉醇50 mg/m2,第1天;卡铂AUC=2,第1天。
- 主要终点2年局部控制率为87.9%(95%CI:83.3-92.3)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To compare the efficacy and safety of postoperative extensive target volume irradiation with elevated radiation dose and concurrent chemotherapy with radiotherapy only for the postoperative treatment of esophageal squamous cell carcinoma. METHODS: This trial was a single-arm phase II trial. Patients who underwent a radical transthoracic resection with negative margins within 3 months and histologically confirmed esophageal squamous cell carcinoma (pT3-4N0M0 or pTxN + M0, AJCC 7th) were eligible for this study. Postoperative radiotherapy was performed at a total dose of 45 Gy in 25 fractions with clinical target volumes of the tumor bed, anastomosis, bilateral supraclavicular, mediastinal, left gastric and celiac trunk lymph node areas. Five cycles of weekly TC (paclitaxel 50 mg/m2, d1, carboplatin AUC = 2, d1) were given as concurrent chemotherapy. The primary endpoint was the 2-year local control rate, and the secondary endpoints were overall survival, disease free survival, local-regional recurrence free survival, distant metastasis free survival and adverse events. All endpoints were compared with those in ESO-Shanghai 8 study with postoperative radiotherapy alone (40 Gy/20Fx). RESULTS: A total of 70 patients were enrolled from 2016 to 2018. The 2-year local control rate was 87.9% (95% CI: 83.3-92.3) in this study, which achieved the hypothesized 2-year local control rate of at least 83%. Overall survival, disease free survival, local-regional recurrence free survival and distant metastasis free survival in this study were also longer than those in previous ESO-Shanghai 8 study while most toxicities were increased and two patients in this study died of radiation pneumonitis. CONCLUSIONS: Postoperative extensive target volume irradiation with elevated radiation dose and concurrent chemotherapy was effective. Treatment related toxicity was increased due to higher treatment intensity. Trial registration clinicaltrials.gov: NCT02916511.
引用
- Ai D, Chen Y, Liu Q, et al. Extensive clinical target volume in postoperative chemoradiotherapy for esophageal squamous cell carcinoma: a phase II clinical trial (ESO-Shanghai 9). Radiat Oncol. 2023. PMID: 36750858. doi:10.1186/s13014-023-02211-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。